Oncology
PL BioScience and DewCell sign LOI to Jointly Develop Artificial Human Platelets for Scalable, Animal-Free Cell Culture Media
May 23, 2025Research and Development Animal-Free, Artificial Human Platelets, Corporate, DewCell, Haematology, Human Platelet Lysate, Letter of Intent, Oncology, PL Bioscience
PL BioScience and DewCell Biotherapeutics have signed a Letter of Intent (LOI) for the development and supply of artificial human …
Novartis releases new data across oncology and haematology pipelines
May 21, 2025Research and Development ASCO, EHA, Haematology, Novartis, Oncology, oncology
Novartis has announced it will present new data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking …
Multiple myeloma treatment approved in Japan
May 21, 2025Market Access, Research and Development, Sales and Marketing GSK, Japan, Oncology, Orphan Drug Designation (ODD), multiple myeloma
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and Welfare for the treatment of …
FDA approves Incyte’s new anal cancer treatment
May 20, 2025Research and Development FDA, Incyte Corporation, Oncology, Orphan Drug Designation (ODD), Zynyz, fast track designation, priority review
The US Food and Drug Administration (FDA) has approved Incyte Corporation’s immunotherapy retifanlimab-dlwr (Zynyz) in combination with carboplatin and paclitaxel to treat …
Landmark BioVentures launches spin-off biotech to tackle fibrotic, neoplastic and neovascularised conditions
May 20, 2025Research and Development Aix-Marseille University, Cardiology, Corporate, Landmark BioVentures, Massalia Therapeutics, Oncology, cardiovascular research, oncology
Landmark BioVentures and researchers at Aix-Marseille University in Marseille, France, have launched Massalia Therapeutics. Marking Landmark’s seventh company, the spin-off …
FDA approves diagnostic tool for MET-targeted lung cancer therapy
May 19, 2025Research and Development FDA, Oncology, Roche, lung cancer, non-squamous non-small cell lung cancer
The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay as a diagnostic tool to …
Medable unveils oncology trial platform aimed at reducing logistical hurdles
May 16, 2025Biotech/start-up, Business Services, Research and Development, Sales and Marketing, Technical Consultancy AI, FDA, Medable, Oncology, digital platform, oncology research, oncology trials
Clinical trial technology provider, Medable, has launched a digital platform designed to support oncology clinical trials by addressing growing operational …
Moleculin secures EMA approval to expand acute myeloid leukaemia trial across EU
May 16, 2025Research and Development Clinical Trial Application (CTA), European Union (EU), FDA, Food and Drug Administration, Moleculin Biotech, Oncology, Orphan Drug Designation (ODD), acute myeloid leukaemia
Moleculin Biotech has received approval from the European Medicines Agency (EMA) to expand its phase 3 ‘MIRACLE’ trial into nine …
Thermosome secures FDA Orphan Drug Designation for soft tissue sarcoma therapy
May 12, 2025Research and Development European Medicines Agency (EMA), FDA, Oncology, Thermosome
Thermosome has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its lead candidate, THE001, …
Genmab to submit FDA application for lymphoma therapy
May 2, 2025Research and Development AbbVie, Biologics License Application, FDA, Genmab, Oncology, epcoritamab, lymphoma, therapeutics
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) …
Ambitious plans for leading cancer research centre announced
May 2, 2025Market & Product Development, Medical Communications, Research and Development Aviva Capital Partners (ACP), Institute of Cancer Research (ICR), London, London Cancer Hub, Oncology, Royal Marsden NHS Foundation Trust, Socius
Aviva Capital Partners (ACP), an infrastructure and real estate investor, and Socius, a mixed-use developer, have unveiled plans for a …
Deadly cancers are being financially left behind, new research claims
May 1, 2025Research and Development Jude, Oncology, UK, bladder cancer, cancer research, charitable funding
New research has revealed that some of the UK’s most deadly and prevalent cancers receive the least amount of charitable …
Neogap chosen for Innovate Nordics 2025 Acceleration Programme
May 1, 2025Research and Development Innovate Nordics, Neogap Therapeutics, Oncology, biotech, funding programme, immunotherapy
Swedish biotech company Neogap Therapeutics has been chosen to join Innovate Nordics’ 2025 acceleration programme, a prestigious initiative designed to …
Cervical cancer experts campaign to increase screening rates and save lives
April 30, 2025Research and Development NHS, NHS England, Oncology, campaign, cervical cancer, screening
A coalition of experts fighting to end cervical cancer, referred to as the UK Consensus Group of the Advancing Cervical …
McDavid Stilwell appointed as CFO of CPTx
April 28, 2025Research and Development CPTx, Immunology, Oncology, appointment, cfo, therapeutics
CPTx, a German biotech company focused on single-stranded DNA therapeutics, has announced the appointment of McDavid Stilwell as chief financial …
Latest content
FibroFind appoints Lee Borthwick as CEO
